Moolec Science (MLEC) Debt to Equity (2023 - 2025)

Moolec Science's (MLEC) quarterly Debt to Equity came in at -$3.46 in Q2 2025, down 101.16% year-on-year from $298.28 in Q2 2024, and down 101.16% quarter-over-quarter from $298.28 in Q2 2024.

Moolec Science (MLEC) Debt to Equity (2023 - 2025) Analysis & Trends

Moolec Science has disclosed Debt to Equity across 3 years of filings, most recently posting -$3.46 for Q2 2025.

  • Debt to Equity for Q2 2025 came in at -$3.46, down 101.16% year-over-year; the trailing twelve-month figure through Jun 2025 was -$3.46 (down 101.16% YoY), and the FY2025 annual result was -$3.46, down 101.16% from the prior year.
  • Debt to Equity came in at -$3.46 for Q2 2025 at Moolec Science, down from $298.28 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $298.28 in Q2 2024 to a low of -$3.46 in Q2 2025.
  • The 3-year median for Debt to Equity is $0.06 (2023), against an average of $98.29.
  • Across the five-year window, Debt to Equity surged 530622.1% in 2024 and sank 101.16% in 2025, its largest moves.
  • Moolec Science's Debt to Equity stood at $0.06 in 2023, then soared by 530622.1% to $298.28 in 2024, then slumped by 101.16% to -$3.46 in 2025.
  • The last three Debt to Equity figures came in at -$3.46 (Q2 2025), $298.28 (Q2 2024), and $0.06 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Moolec Science 6.98 Bn 6.98 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -3.46
Jun 30, 2024 298.28
Jun 30, 2023 0.06